

John Slof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2670849/publications.pdf>

Version: 2024-02-01

10
papers

129
citations

1307366

7
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

183
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of waiting for intervention on costs and effectiveness: the case of transcatheter aortic valve replacement. <i>European Journal of Health Economics</i> , 2018, 19, 945-956.	1.4	8
2	Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 67-76.	0.7	7
3	Transfemoral transcatheter aortic valve replacement compared with surgical replacement in patients with severe aortic stenosis and comparable risk: Cost-utility and its determinants. <i>International Journal of Cardiology</i> , 2015, 182, 321-328.	0.8	31
4	Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 379-391.	0.7	14
5	Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 439-441.	0.7	27
6	Cost-Effectiveness Analysis of Early versus Non-Early Intervention in Acute Migraine Based on Evidence from the Act when Mild™ Study. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 201-215.	1.0	9
7	Assessing the Impact of Fair Value Accounting on Financial Statement Analysis: A Data Envelopment Analysis Approach. <i>Abacus</i> , 2011, 47, 61-84.	0.9	24
8	From design of activity-based costing systems to their regular use. <i>Intangible Capital</i> , 2011, 7, .	0.6	0
9	Zoledronic acid versus pamidronate: cost minimisation in bone metastasis. <i>Journal of Medical Economics</i> , 2005, 8, 1-12.	1.0	3
10	Cost-efficacy of oral triptans in the treatment of acute migraine. <i>Journal of Medical Economics</i> , 2005, 8, 27-43.	1.0	4